US › Healthcare

Myriad Genetics Inc (MYGN)

US · Healthcare · Diagnostics & Research

$3.17+4.97%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$200.4M
Revenue YoY
+2.3%
Net profit
$-34.1M
Profit YoY
-34000.0%
EPS
$-0.09
EPS estimate
$-0.07
Net margin
-17.0%

EPS came in at -0.09 against a street estimate of -0.07 — a miss of 28.6%.

Key statistics

Market cap
$285.2M
Forward P/E
46.1
P/B
0.89
Book value
$3.57
EPS (TTM)
$-1.18
52-week high
$8.59
52-week low
$2.74
50-day MA
$5.04
200-day MA
$5.59
Beta
1.64

Analyst view

Analysts rate Myriad Genetics Inc a hold (6 buy, 6 hold, 3 sell out of 15) with an average price target of $6.25.

Shareholding

Insiders
3.76%
Institutions
96.18%

Largest institutional holders

FundStake
BlackRock Inc9.41%
Vanguard Group Inc8.71%
Millennium Management LLC7.06%
Glenview Capital Management LLC5.73%
D. E. Shaw & Co LP4.76%
State Street Corp4.68%
Vanguard Capital Management, LLC4.16%
Morgan Stanley - Brokerage Accounts3.35%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Myriad Genetics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.